Analysis of Liposomal irinotecan's pharmacokinetics and side effects

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1041200085

Enrollment

Registered

2020-12-25

Start date

2020-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer Pancreatic cancer Onyvyde Irinotecan UGT1A1

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic cancer, underwent UGT1A1 polymorphism test

Exclusion criteria

Exclusion criteria: Already used Onivyde(Liposomal irinotecan)

Design outcomes

Primary

Measure	Time frame
Comparison of drug concentration of Irinotecan and its metabolites by UGT1A1 gene polymorphism	—

Secondary

Measure	Time frame
Secondary Outcome(s)Adverse events, Time to treatment failure, Effectiveness (Response rate, progression-free survival, Overall survival)	—

Contacts

Public ContactSatoshi FURUNE

Nagoya University Hospital

s-furune@med.nagoya-u.ac.jp+81-527442172

Outcome results